Wolfspeed bankruptcy watch, North Carolina lands more data centers, Duke University's funding crunch, and an AI companion ...

Amgen faces major revenue risk from upcoming patent cliffs but has promising pipeline drugs to offset losses. Learn why AMGN ...

The row between pharma companies and the U.K. government over rebates has intensified, with the Association of the British Pharmaceutical Industry (ABPI) calling up its members to speak on the record, ...

Sanofi and BMS paid big money for rare disease and cancer assets, while Regeneron got in the obesity game; AstraZeneca, Gilead and Amgen shone at ASCO; RFK Jr. and the CDC appeared to disagree over ...

Billions of dollars worth of U.S. biomanufacturing plant development has been announced, and site selection will likely be ...

Discover how biotechs and big pharma are developing novel treatments for high cholesterol with a range of different targets.

In the latest episode of The Top Line podcast, host Heath Clendenning interviews Cheryl Lubbert, CEO of Reverba Global, to ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Boston Common Asset Management dramatically boosted its Amgen holdings by 129%, snapping up nearly 50,000 shares worth $15.49 ...

Vepdegestrant, an investigational estrogen receptor (ER) degrader, known as a proteolysis-targeting chimera (PROTAC ), ...

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take ...